Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Up 6.6% – Here’s What Happened

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) shares shot up 6.6% during trading on Wednesday . The company traded as high as $11.9620 and last traded at $11.9620. 521 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 13,901 shares. The stock had previously closed at $11.22.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Down 0.5%

The firm’s 50 day simple moving average is $11.33 and its two-hundred day simple moving average is $10.92. The firm has a market cap of $3.83 billion and a price-to-earnings ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.